Madrigal Pharmaceuticals, Inc. (MDGL)’s Insider Marc Schneebaum Sold 10,099 Shares; Cornercap Investment Counsel Lowered By $868,144 Its Magellan Midstream Prtnrs LP C (MMP) Position

Cornercap Investment Counsel Inc decreased Magellan Midstream Prtnrs Lp C (MMP) stake by 75.05% reported in 2018Q1 SEC filing. Cornercap Investment Counsel Inc sold 14,968 shares as Magellan Midstream Prtnrs Lp C (MMP)’s stock rose 5.46%. The Cornercap Investment Counsel Inc holds 4,975 shares with $291,000 value, down from 19,943 last quarter. Magellan Midstream Prtnrs Lp C now has $15.99 billion valuation. The stock decreased 0.99% or $0.7 during the last trading session, reaching $70.07. About 353,568 shares traded. Magellan Midstream Partners, L.P. (NYSE:MMP) has declined 7.22% since June 13, 2017 and is downtrending. It has underperformed by 19.79% the S&P500. Some Historical MMP News: ; 02/05/2018 – MMP CONSIDERING CONSTRUCTION OF A NEW REFINED PRODUCTS TERMINAL; 20/04/2018 – DJ Magellan Midstream Partners LP, Inst Holders, 1Q 2018 (MMP); 02/05/2018 – MAGELLAN MIDSTREAM BOOSTS SCOPE & EXTENDS OPEN SEASON; 12/04/2018 – BridgeTex crude pipeline cancels low spot rate as demand rises; 29/05/2018 – Steve Madden Selects MMP’s INCITE Platform to “Step-Up” Empowerment of Front Line Associates & Impact the In-Store Experience; 09/04/2018 – MAGELLAN MIDSTREAM PARTNERS LP MMP.N : RBC RAISES TO OUTPERFORM FROM SECTOR PERFORM; 03/05/2018 – Magellan Midstream Sees 2Q EPS 95c; 03/05/2018 – Magellan Midstream 1Q Adj EPS 98c; 23/05/2018 – Singapore Bourse: Change In Mmp Resources Limited; 09/04/2018 – Cramer also sits down with the CEO of Magellan Midstream Partners

Analysts await Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to report earnings on August, 9. They expect $-0.60 earnings per share, up 13.04% or $0.09 from last year’s $-0.69 per share. After $-0.45 actual earnings per share reported by Madrigal Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $4.77 billion. The company's lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

The stock increased 10.80% or $30.53 during the last trading session, reaching $313.24. About 1.26M shares traded or 206.39% up from the average. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has risen 630.32% since June 13, 2017 and is uptrending. It has outperformed by 617.75% the S&P500. Some Historical MDGL News: ; 31/05/2018 – MADRIGAL PHARMACEUTICALS INC – MGL-3196 WAS WELL-TOLERATED WITH MOSTLY MILD AND A FEW MODERATE AES; 08/05/2018 – MADRIGAL PHARMA 1Q CASH & OTHER $182.8M; 31/05/2018 – MADRIGAL’S MGL-3196 ACHIEVES LIVER BIOPSY ENDPOINTS IN PATIENTS; 31/05/2018 – STAT Plus: With positive data, Madrigal Pharma joins lucrative race for drug to treat fatty liver disease; 15/05/2018 – Capital Group Companies Buys 7.4% Position in Madrigal Pharma; 13/03/2018 – MADRIGAL PHARMACEUTICALS INC – QTRLY SHR LOSS $0.67; 13/03/2018 – MADRIGAL PHARMA 4Q LOSS/SHR 67C, EST. LOSS/SHR 70C; 13/03/2018 – MADRIGAL PHARMACEUTICALS INC – CO IS IN A “STRONG” FINANCIAL POSITION TO ADVANCE MGL-3196 IN BOTH INDICATIONS; 31/05/2018 – MADRIGAL PHARMACEUTICALS -PHASE 2 CLINICAL TRIAL OF MGL-3196 ALSO SHOWED STATISTICALLY SIGNIFICANT RESULTS IN KEY SECONDARY ENDPOINTS; 08/05/2018 – MADRIGAL PHARMACEUTICALS INC QTRLY SHR LOSS $0.45

Two days ago, the Chief Financial Officer of Madrigal Pharmaceuticals Inc, Mr. Marc Schneebaum, made a sale of a huge number of company shares – 10,099, totalling $2,903,059 U.S. Dollars, which is based on a market stock price of $287.5 for share. The sell will most probably not stay disregarded as it was significant. At present, he owns a total of 41,668 shares or 0.27% of Madrigal Pharmaceuticals Inc’s market capitalization.

More notable recent Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news were published by: Benzinga.com which released: “Maxim Explains Viking Therapeutics’ Sympathy Move With Madrigal” on June 02, 2018, also Globenewswire.com with their article: “Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock” published on June 05, 2018, Globenewswire.com published: “Madrigal Pharmaceuticals Prices Public Offering of Common Stock” on June 07, 2018. More interesting news about Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) were released by: Streetinsider.com and their article: “Pre-Open Movers 05/31: (MDGL) (VTVT) (GM) Higher; (CLSD) (CRSP) (DLTR) Lower (more..)” published on May 31, 2018 as well as Nasdaq.com‘s news article titled: “Why Viking Therapeutics Stock Is On Fire Today” with publication date: May 31, 2018.

Among 23 analysts covering Magellan Midstream Partners L.P. (NYSE:MMP), 13 have Buy rating, 3 Sell and 7 Hold. Therefore 57% are positive. Magellan Midstream Partners L.P. had 68 analyst reports since August 7, 2015 according to SRatingsIntel. Morgan Stanley maintained Magellan Midstream Partners, L.P. (NYSE:MMP) rating on Friday, March 16. Morgan Stanley has “Underweight” rating and $69 target. The rating was maintained by Mizuho with “Neutral” on Monday, February 6. The firm earned “Hold” rating on Sunday, August 27 by RBC Capital Markets. The stock of Magellan Midstream Partners, L.P. (NYSE:MMP) has “Hold” rating given on Thursday, February 1 by RBC Capital Markets. The rating was initiated by DA Davidson on Monday, November 16 with “Buy”. The firm earned “Equal-Weight” rating on Tuesday, April 17 by Barclays Capital. On Tuesday, March 13 the stock rating was maintained by JP Morgan with “Neutral”. The stock has “Underperform” rating by Mizuho on Monday, July 10. The firm has “Buy” rating by Ladenburg Thalmann given on Wednesday, July 13. Stifel Nicolaus maintained the stock with “Hold” rating in Thursday, September 7 report.

More notable recent Magellan Midstream Partners, L.P. (NYSE:MMP) news were published by: Fool.com which released: “3 Energy Stocks You Don’t Have to Babysit” on June 12, 2018, also Fool.com with their article: “The Permian Basin’s Pipeline Woes Are Bad News for Some Investors but a Boon for Others” published on June 11, 2018, Seekingalpha.com published: “Energy Transfer Partners restores power to West Texas facility” on June 08, 2018. More interesting news about Magellan Midstream Partners, L.P. (NYSE:MMP) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Eldorado Gold, Lamar Advertising, Bitauto …” published on June 07, 2018 as well as Fool.com‘s news article titled: “This Is One Impressive Dividend Growth Stock” with publication date: June 09, 2018.

Cornercap Investment Counsel Inc increased Cognizant Technology Solutions (NASDAQ:CTSH) stake by 18,947 shares to 73,793 valued at $5.94M in 2018Q1. It also upped Avangrid Inc Com stake by 11,968 shares and now owns 103,118 shares. Molson Coors Brewing Co Cl B (NYSE:TAP) was raised too.

Analysts await Magellan Midstream Partners, L.P. (NYSE:MMP) to report earnings on August, 1. They expect $1.00 EPS, up 8.70% or $0.08 from last year’s $0.92 per share. MMP’s profit will be $228.20 million for 17.52 P/E if the $1.00 EPS becomes a reality. After $1.05 actual EPS reported by Magellan Midstream Partners, L.P. for the previous quarter, Wall Street now forecasts -4.76% negative EPS growth.

Investors sentiment increased to 0.78 in Q1 2018. Its up 0.02, from 0.76 in 2017Q4. It increased, as 48 investors sold MMP shares while 175 reduced holdings. 42 funds opened positions while 131 raised stakes. 135.98 million shares or 1.03% more from 134.60 million shares in 2017Q4 were reported. Fiera Capital has invested 0.01% in Magellan Midstream Partners, L.P. (NYSE:MMP). Oxbow Advisors Limited Liability Company reported 0.17% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP). Gamble Jones Counsel has invested 0.02% in Magellan Midstream Partners, L.P. (NYSE:MMP). First Western Mngmt reported 1.68% in Magellan Midstream Partners, L.P. (NYSE:MMP). Automobile Association reported 235,848 shares stake. Argent Tru Company holds 0.18% or 10,660 shares in its portfolio. Fulton Bank & Trust Na has invested 0.03% in Magellan Midstream Partners, L.P. (NYSE:MMP). Thomaspartners Inc reported 295,341 shares. Brown Advisory Limited Com holds 7,740 shares or 0.08% of its portfolio. Moreover, Stratos Wealth Prtn has 0.04% invested in Magellan Midstream Partners, L.P. (NYSE:MMP). Bridges Inv Mngmt holds 0.03% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP) for 12,128 shares. Mcdaniel Terry stated it has 0.09% in Magellan Midstream Partners, L.P. (NYSE:MMP). Private Ocean Limited stated it has 350 shares or 0.01% of all its holdings. Camarda Financial Advsrs Limited holds 0.13% or 2,204 shares. Parsec Management has 0.01% invested in Magellan Midstream Partners, L.P. (NYSE:MMP) for 3,486 shares.

Since February 12, 2018, it had 0 insider buys, and 1 sale for $1.51 million activity. $1.51 million worth of Magellan Midstream Partners, L.P. (NYSE:MMP) was sold by MEARS MICHAEL N on Monday, February 12.

Magellan Midstream Partners, L.P. (NYSE:MMP) Institutional Positions Chart